Alpha 1-Antitrypsin Deficiency clinical trials at UCSD
2 in progress, 1 open to eligible people
Alpha-1 Antitrypsin Deficiency Adult Liver Study
open to eligible people ages 18 years and up
The investigators hypothesize that there is liver injury (inflammation, fibrosis, cirrhosis) in adults with Alpha-1 Antitrypsin Deficiency (AATD), which is asymptomatic, under-recognized, and undiagnosed. In addition, the investigators believe that the genetic and environmental factors that play an important role in the development of alpha-1 antitrypsin (AAT) liver disease, can be identified by comparing a cohort database of clinical disease information to linked biospecimen and DNA samples.
San Diego, California and other locations
Safety, Tolerability and Pharmacodynamic Effect of ARO-AAT
Sorry, in progress, not accepting new patients
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, ARO-AAT, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
La Jolla, California and other locations
Last updated: